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This phase I study assessed the safety, pharmacokinetics, and
efficacy of gefitinib (IRESSA) combined with vinorelbine or vi-
norelbine/cisplatin in chemotherapy-naive patients with advanced
non-small cell lung cancer (NSCLC). Patients received gefitinib 250
mg/day and vinorelbine (group A; n  6) or vinorelbine/cisplatin
(group B; n  8). An additional set of group B patients (n  9)
received gefitinib 500 mg/day with vinorelbine/cisplatin. Adverse
events were consistent with individual treatments of gefitinib (mild
reversible rash, diarrhea) and chemotherapy (asthenia, fever, nausea,
vomiting, constipation), although there was a higher than expected
incidence of Common Toxicity Criteria grade 3 or 4 hematologic
adverse events, specifically febrile neutropenia and neutropenia.
Pharmacokinetic data suggested that neither of the chemotherapy
regimens affected steady-state exposure to gefitinib and also that
steady-state gefitinib did not alter exposure to vinorelbine or cispla-
tin. Objective, durable antitumor activity was observed: five partial
responses (one in group A; four in group B) and six patients with
stable disease (all in group B). The safety data demonstrated that
gefitinib with vinorelbine or vinorelbine/cisplatin resulted in severe
myelosuppression leading to an unacceptable rate of febrile neutro-
penia. This study does not support the concurrent administration of
gefitinib and vinorelbine, with or without cisplatin, as a valid
treatment for advanced NSCLC.
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Lung cancer is currently the most lethal tumor type inWestern countries, accounting for approximately 1 million
deaths annually, with an estimated 1.32 million people newly
diagnosed with the disease each year.1 Among the different
histologic types, non-small cell lung cancer (NSCLC) re-
mains an important challenge for medical oncology because
most patients are diagnosed at an advanced stage of disease.
Most patients with advanced NSCLC (stage IV or IIIB
with pleural or pericardial malignant effusion) are not eligible
for surgery or radiotherapy. However, chemotherapy is cur-
rently the standard treatment option for patients able to
tolerate aggressive therapy.2 Studies reporting data for che-
motherapy for inoperable stage IIIB/IV disease show a me-
dian survival of only approximately 8 months, a 1-year
survival rate of 35%, and 5-year survival rate of 5%.3,4
Platinum-based combinations have been accepted as a stan-
dard for the treatment of advanced or metastatic NSCLC,
based on the results of phase III randomized trials and the
meta-analysis by the NSCLC Collaborative Group published
in 1995.4,5 However, better treatment strategies are badly
needed, and the investigation of combinations of novel agents
with chemotherapy for first-line treatment is of great interest.
Gefitinib (IRESSA), an anilinoquinazoline, is an orally
active inhibitor of epidermal growth factor receptor tyrosine
kinase, an enzyme that catalyzes phosphorylation reactions
implicated in the proliferation and survival of cancer cells via
intracellular signal transduction pathways. In phase II trials of
gefitinib monotherapy in patients with previously treated,
locally advanced or metastatic NSCLC, gefitinib 250 mg/day
demonstrated clinically significant antitumor activity as evi-
denced by durable tumor responses (objective response rate,
12%–18%), disease control (rate, 42%–54%), and improve-
ment in disease-related symptoms in 40% to 43% of pa-
tients.6,7 Adverse events (AEs) consisted predominantly of
mild (grades 1–2) diarrhea and skin reactions. The dose of
gefitinib 500 mg/day produced a higher frequency of AEs but
did not increase efficacy.6,7
The potential for combining gefitinib and chemother-
apy, which have largely nonoverlapping toxicity profiles, has
been shown in preclinical studies in which the antitumor
activity of gefitinib was enhanced when used in combination
with a number of cytotoxic drugs.8,9 Furthermore, data from
phase I trials showed that combinations of gefitinib with
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carboplatin/paclitaxel in patients with NSCLC and with cis-
platin/gemcitabine in patients with advanced metastatic solid
tumors showed antitumor activity and were generally well
tolerated with no apparent increase in higher grade toxicity.10
The combination of gefitinib and chemotherapy did not cause
an increase in exposure to any of the chemotherapy agents
tested, although increased exposure to gefitinib was seen with
the carboplatin/paclitaxel regimen. There was no evidence
that gefitinib had an antagonistic effect on the efficacy of
chemotherapy.10 In phase III trials in chemotherapy-naive
patients with advanced NSCLC, the addition of gefitinib to
paclitaxel/carboplatin or gemcitabine/cisplatin gave no added
survival benefit.11,12 However, the combination of gefitinib
with vinorelbine/cisplatin in this population has not been
reported until now. Single-agent vinorelbine has demon-
strated clinical activity in a number of phase I and II studies,
with overall response rates in NSCLC patients of 14% to 30%
using the standard schedule of 30 mg/m2 per week.13 In a
prospective, randomized trial to compare vinorelbine and
cisplatin with vindesine and cisplatin, improved response rate
and survival versus single-agent vinorelbine was seen in the
vinorelbine/cisplatin arm: response rates were 30% for vi-
norelbine/cisplatin versus 19% for vindesine/cisplatin (p 
0.02) and 14% for vinorelbine alone (p  0.001). Median
survival was 40 weeks in the vinorelbine/cisplatin arm com-
pared with 32 weeks in the vindesine/cisplatin arm and 31
weeks for vinorelbine alone.14
The present phase I study was aimed at assessing the
safety and pharmacokinetics of gefitinib when used in com-
bination with vinorelbine and cisplatin. Gefitinib is cleared
primarily by the hepatic route as parent compound plus
metabolites and the major cytochrome P-450 enzyme in-
volved in gefitinib metabolism is CYP3A4.15 Because the
main elimination pathway of vinorelbine is also hepatic
metabolism principally mediated by CYP3A4,16 this raised
the limited possibility of a pharmacokinetic interaction.
METHODS
Trial Design
This was an open pilot trial of two doses of gefitinib
(250 and 500 mg) in combination with chemotherapy in
chemotherapy-naive patients with advanced NSCLC. The
primary objective was to assess the safety of gefitinib when
used in combination with the cytotoxic agents vinorelbine
and cisplatin. Secondary objectives included an assessment of
whether exposure to gefitinib, vinorelbine, or vinorelbine/
cisplatin was altered when the agents were given in combi-
nation and an assessment of antitumor activity.
Patients and Treatment
Patients were chemotherapy naive, had a World Health
Organization performance status (PS) of 2, were age 18
years and older, had histologically confirmed locally ad-
vanced or metastatic NSCLC, and gave written, informed
consent. The trial was performed in accordance with the
Declaration of Helsinki. Criteria that caused patients to be
ineligible for the trial included brain metastasis or spinal cord
compression that was newly diagnosed and/or had not yet
been definitively treated; radiotherapy 2 weeks previously;
other coexisting malignancies or malignancies diagnosed
within the past 5 years with the exception of basal cell
carcinoma or cervical cancer in situ; weight loss of 10% in
the past 3 months; absolute neutrophil count of 2  109
ml1; white blood cell count of 4  109 ml1; and platelet
count of 1011 ml.
The trial was run as two groups of patients, group A
and group B, with patients allocated at the investigators’
discretion. Group A received gefitinib and vinorelbine, and
group B received gefitinib in combination with vinorelbine
and cisplatin. Initially, patients were assigned to oral gefitinib
250 mg/day. In group A, patients received a standard regimen
of vinorelbine (30 mg/m2 intravenously [IV]), administered
on days 1, 8, 15, and 22 of each 28-day cycle and gefitinib
daily starting on day 2. Additional cycles of vinorelbine
concurrently with gefitinib were administered every 4 weeks
for up to six cycles in total. In group B, patients received a
standard chemotherapy regimen of cisplatin (80 mg/m2 IV)
and vinorelbine (30 mg/m2 IV), administered on day 1.
Vinorelbine was also administered on day 8 of each 21-day
cycle and oral gefitinib daily starting on day 2. Additional
cycles of chemotherapy were administered concurrently with
gefitinib every 3 weeks for up to six cycles. For both groups,
at the end of the combination treatment period, benefiting
patients could continue receiving gefitinib monotherapy until
disease progression, withdrawal due to unacceptable toxicity,
or a patient’s unwillingness to continue.
Safety
AEs and laboratory values were graded according to the
National Cancer Institute Common Toxicity Criteria (CTC)
version 2.0. AEs continued to be recorded for a 30-day
follow-up period after the last administration of study treat-
ment. Withdrawn patients who had CTC grade 3 or 4 labo-
ratory values at the time of withdrawal were followed up until
the laboratory values returned to CTC grade 1 or until 30 days
after the date of withdrawal. Patients were evaluated for
safety on day 29 in group A and day 22 in group B. When the
first six assessable patients at the gefitinib 250 mg/day dose
level in each group had completed this period, a full safety
evaluation was performed.
Dose Adjustment
Dose adjustments during a cycle were made based on
weekly absolute granulocyte counts and/or platelet counts.
Vinorelbine was reduced by 25% in the case of an absolute
granulocyte count of 1.2  109/L and/or platelet count of
100  109/L. Vinorelbine was withheld in the case of an
absolute granulocyte count of 1  109/L and/or platelet
count of 75  109/L. Dose adjustments for subsequent
cycles were made based on the toxicity seen in the previous
cycle.
Dose-Limiting Toxicity
Based on the anticipated toxicities of vinorelbine, vi-
norelbine and cisplatin, and gefitinib monotherapy, an indi-
vidual drug-related dose-limiting toxicity (DLT) was defined
as follows: CTC grade 4 thrombocytopenia with severe
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bleeding or grade 4 neutropenia associated with sepsis requir-
ing hospitalization; grade 3/4 skin toxicity; grade 3/4 gastro-
intestinal toxicity (diarrhea for 4 days despite aggressive
antidiarrheal therapy and temporary or permanent discontin-
uation of gefitinib); grade 4 gastrointestinal toxicity (nausea
or vomiting for 4 days despite aggressive antiemetic ther-
apy and temporary or permanent discontinuation of gefitinib);
deterioration of visual acuity or other significant ocular tox-
icity; grade 3/4 central nervous system, cardiac, lung, or renal
toxicity. If there was a higher than expected incidence of
drug-related hepatic toxicity, consideration was given to not
escalating the dose of trial medication.
After the full safety evaluation after cycle 1, if no more
than one patient experienced drug-related DLT among the six
assessable patients, the dose was considered safe and the
500-mg dose level was opened to accrual. If two or three
patients experienced drug-related DLT among the six assess-
able patients, this dose level was expanded to obtain 12
assessable patients. If no more than three patients experi-
enced drug-related DLT among these 12 assessable patients,
the dose was considered safe in combination and the 500-mg
dose level was opened to recruitment. If, however, four or
more patients experienced drug-related DLT among these 12
assessable patients, the dose was not considered safe in
combination and the 500-mg dose level was not opened to
accrual. If four or more patients experienced drug-related
DLT among the first six assessable patients, the dose was not
considered safe in combination and the 500-mg dose level
was not opened to accrual.
Pharmacokinetics
Blood samples for determination of concentrations of
vinorelbine, cisplatin, and gefitinib were obtained during the
first and second cycles of gefitinib and chemotherapy, with
the aim of obtaining satisfactory samples for each agent from
at least four patients at each gefitinib dose level. For vinorel-
bine assessment (groups A and B), a predose sample was
taken on day 1, followed by samples at 15 and 30 minutes and
1, 4, 8, and 24 hours after the start of infusion. This was
repeated on day 22. For cisplatin (group B), samples were
taken on day 1 predose and at 2, 2.5, 3, 4, and 5 hours after
infusion start, also repeated on day 22. For gefitinib (groups
A and B), samples were taken on day 21 at predose and at 3,
7, and 24 hours and on day 22 at 3, 7, and 24 hours (the day
21 24-hour sample also acting as the day 22 predose sample).
The minimum (trough) steady-state plasma concentra-
tion during the 24-hour dosing interval (Cmin
ss) for gefitinib
was taken as the concentration in the predose sample col-
lected on the sampling day when given alone or as the
concentration in the 24-hour sample collected on the sam-
pling day when given in combination with chemotherapy.
The maximum plasma concentration (Cmax) for vinorelbine
and free cisplatin was taken as the concentration determined
at the end of the infusion period for each drug. For each drug,
the area under the plasma concentration-time curve at steady
state ([AUC24
ss] for gefitinib, and from time 0 to time of the
last quantifiable concentration [AUC(0-t)] for vinorelbine and
cisplatin) was calculated using the linear trapezoidal rule.
Efficacy
Tumor response was evaluated according to Response
Evaluation Criteria in Solid Tumors. Patients continuing to
show evidence of response or clinical benefit after completing
the six cycles of combination treatment could continue ge-
fitinib monotherapy as part of the trial protocol.
RESULTS
Patients
A total of 23 patients with advanced NSCLC were
recruited in five centers in France and Canada between
October of 2001 and August of 2002. All patients had
measurable disease at baseline in accordance with Response
Evaluation Criteria in Solid Tumors. Patient demographic
information and key baseline disease characteristics are sum-
marized by dose group (Table 1). The median age was 59
years (range, 24–75), and the majority of patients were PS 0
(60.9%) and had stage IV disease (95.7%). Adenocarcinoma
(52.2%) was the most common histology type. Three patients
had undergone a previous operation, and two had received
radiotherapy for brain metastasis or brain and bony metasta-
ses, respectively. Overall, patients in the gefitinib 250-mg
group in group B were younger and heavier and had a better
PS compared with the other treatment groups.
Treatment
All 23 patients who entered the trial received gefitinib
concurrently with at least one cycle of chemotherapy. The
mean number of cycles received was 2.3 in group A and 4.6
in group B. A trial flow schema showing patient numbers is
TABLE 1. Baseline Demographics
Patients, no. 23
Group A: gefitinib 250 mg 6
Group B: gefitinib 250 mg 8
Group B: gefitinib 500 mg 9
Age, yr (range) 59 (24–75)
Female:male, no. 10:13
World Health Organization PS 0/1, no. 14/9
Disease stage IIIB/IV, no. 1/22
Histology type, no. (%)
Adenocarcinoma 12 (52.2)
Large cell 6 (26.1)
Squamous cell 3 (13.0)
Undifferentiated 2 (8.7)
Metastatic sites, no. (%)
Adrenal 4 (17.4)
Bone 9 (39.1)
Lymph nodes 3 (13.0)
Lung (other than primary tumor) 14 (60.9)
Skin/soft tissue 2 (8.7)
Liver 4 (17.4)
Brain 2 (8.7)
Renal 1 (4.3)
PS, performance status.
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illustrated in Figure 1. Eleven patients remained in the trial
for 6 months and 10 patients for 3 months: eight patients
were ongoing at the time of the data cutoff (January of 2003).
In the gefitinib plus vinorelbine single-drug chemother-
apy arm, no patients entered the 500-mg dose level: a review
of the data from the present trial and a concurrent study17
indicated an unexpectedly high number of hematologic
events (febrile neutropenia and grade 3/4 neutropenia) than
would have been anticipated with single-agent vinorelbine.
After discussing these data, a decision was made not to
escalate the dose to 500 mg.
Dose Reductions/Delays
Nineteen patients (six in group A, five receiving ge-
fitinib 250 mg/day in group B, and eight receiving gefitinib
500 mg/day in group B) had either a dose reduction or cycle
delay of vinorelbine due to typical events that were consid-
ered to be chemotherapy related, including febrile neutrope-
nia, neutropenia (grade 3/4), anemia, and weight loss.
Thirteen patients (five patients receiving gefitinib 250
mg/day and eight patients receiving gefitinib 500 mg/day in
group B) had either a dose reduction or cycle delay of
cisplatin due to chemotherapy-related events, including fe-
brile neutropenia, neutropenia, nausea, weight loss, and re-
duced creatinine clearance. Thirteen patients had one or more
interruptions to their gefitinib therapy due to toxicity: four
patients in group A, two of whom had two interruptions each
(esophagitis [one event], febrile neutropenia [three events], di-
arrhea [one event] and unidentified toxicities [one event]); three
patients in gefitinib 250-mg group B (increased aminotrans-
ferases [one event], diarrhea, asthenia, skin rash, and anemia
[one event], and acne [one event]); and six patients in gefitinib
500-mg group B (neutropenia [three events], diarrhea [two
events], febrile neutropenia [two events, one with concomitant
hyponatremia], acne and gastritis [one event]).
Tolerability
DLT
Two patients experienced protocol-defined DLT. In
group A, one patient experienced a fatal occurrence of grade
4 febrile neutropenia 3 days after the last vinorelbine admin-
istration and after 24 days of gefitinib 250 mg/day treatment.
In the gefitinib 500-mg group in group B, one patient expe-
rienced grade 3 skin toxicity after 20 days of gefitinib
treatment.
AEs
In the combination period, the most common AEs
overall (15% in any treatment group) included diarrhea,
febrile neutropenia, neutropenia, asthenia, stomatitis, anemia,
and rash (Table 2). Events that were part of the chemotherapy
toxicity profile included asthenia, fever, nausea, vomiting,
constipation, and hematologic toxicity. During the gefitinib
monotherapy period, grade 1 or 2 diarrhea was the most
frequently occurring AE (one and two patients in the 250- and
500-mg dose groups in group B, respectively). There were no
serious AEs, withdrawals due to AEs, CTC grade 3 or 4 AEs,
or deaths due to AEs during the monotherapy period.
The frequency of common events was generally similar
between the two chemotherapy regimens and the two dose
groups in group B. A total of 21 patients had grade 3 or 4 AEs
during the combination period of this trial: six in group A, six
in the 250-mg dose group in group B and nine in the 500-mg
dose group in group B (Table 3). The most frequently
reported grade 3 AEs during the combination period were
febrile neutropenia, anemia, and neutropenia. CTC grade 4
AEs included asthenia, chest pain, mucositis, neutropenia,
and febrile neutropenia. With the exception of febrile neutro-
penia and neutropenia, none of the grade 4 AEs were reported
by more than one patient.
Grade 3 or 4 neutropenia affected four of six patients in
group A. There was a higher incidence (50%) of grade 3/4
febrile neutropenia and neutropenia in group A and in the
gefitinib 500-mg group in group B compared with the ge-
fitinib 250-mg group in group B, although, based on the small
number of patients involved, no robust conclusions on fre-
quency can be drawn. The majority of hematologic AEs were
not considered to be related to gefitinib therapy, and there
were none during the monotherapy period. Laboratory data
supported this overall finding on neutropenia: 62% of
patients in each of the treatment groups had a four-grade
worsening of their absolute neutrophil count during the study.
Withdrawals
The overall withdrawal rate was 65.2% (15 of 23
patients). Withdrawal rates by treatment group were 83.3%
(five of six patients) in group A (gefitinib 250 mg); 75.0%
(six of eight) in group B (gefitinib 250 mg); 44.4% (four of
nine) in group B (gefitinib 500 mg). The most common
reason for withdrawal was disease progression, with 33.3% of
patients (gefitinib 250 mg) in group A and 75.0% (gefitinib
250 mg) and 33.3% (gefitinib 500 mg) in group B. AEs
accounted for only one withdrawal: grade 3 pneumonitis in a
FIGURE 1. Flow diagram of the clinical trial.
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patient taking gefitinib 500 mg in group B that was consid-
ered to be due to both gefitinib and chemotherapy.
A total of 11 patients died during the trial, 10 because
of progression of NSCLC. One patient in group A died as a
consequence of febrile neutropenia that was judged to be
treatment related and therefore qualified as a DLT.
Pharmacokinetics
Effect of gefitinib on exposure to vinorelbine.
For gefitinib plus vinorelbine plus cisplatin (group B),
the geometric mean (gmean) AUC(0-t) for vinorelbine was
10% higher in the presence of steady-state levels of gefitinib
250 mg compared with chemotherapy alone and 14% higher
with gefitinib 500 mg (Table 4). The gmean vinorelbine Cmax
was 18% and 6% higher for the 250 mg and 500 mg dose
levels, respectively. For group A (gefitinib 250 mg plus
vinorelbine), the gmean AUC(0-t) and Cmax for vinorelbine
were 16% and 50% lower, respectively, in the presence of
steady-state levels of gefitinib when compared with the che-
motherapy alone (Table 4).
Comparison of individual AUC(0-t) ratios suggested
that there was no tendency toward either a lower or higher
exposure to vinorelbine, irrespective of treatment arm or
gefitinib dose level. Individual Cmax ratios showed similar
results (Table 4). For vinorelbine alone, the population intra-
individual variation equates to mean individual ratios ranging
from 0.60 to 1.67. Hence, there would appear to be no effect
on exposure to vinorelbine when it is given either alone or
with cisplatin in the presence of steady-state levels of ge-
fitinib.
Effect of chemotherapy on exposure to gefitinib.
No patient exceeded the twofold intrasubject variability
exposure to gefitinib and comparison of individual AUC(0-t)
TABLE 2. Adverse Events with an Overall Incidence of 15% during the Combination Period
Group A Group B All Patients (n  23)
Gefitinib 250 mg
 Vinorelbine(n  6)
Gefitinib 250 mg 
Vinorelbine  Cisplatin (n  8)
Gefitinib 500 mg 
Vinorelbine  Cisplatin (n  9) No. (%)
Diarrhea 4 7 8 19 (82.6)
Neutropenia 4 4 8 16 (69.6)
Asthenia 3 5 6 14 (60.9)
Anaemia 3 5 4 12 (52.2)
Febrile neutropenia 4 2 6 12 (52.2)
Stomatitis 4 5 3 12 (52.2)
Rash 2 4 5 11 (47.8)
Fever 2 5 3 10 (43.5)
Nausea 0 5 5 10 (43.5)
Constipation 1 5 3 9 (39.1)
Vomiting 1 4 3 8 (34.8)
Weight loss 3 2 2 7 (30.4)
Anorexia 3 2 1 6 (26.1)
Chest pain 0 1 4 5 (21.7)
Abdominal pain 1 2 1 4 (17.4)
Hypokalemia 1 0 3 4 (17.4)
Insomnia 1 1 2 4 (17.4)
TABLE 3. Common Toxicity Criteria Grade 3 (or 4 If Indicated) Adverse Events Occurring in at Least One Patient during the
Combination Period: All Patients Entered into Trial
Group A Group B
Body System COSTART Term Gefitinib 250 mg (n  6) Gefitinib 250 mg (n  8) Gefitinib 500 mg (n  9)
Whole body Asthenia* 1/0 0/0 2/1
Cardiovascular Pulmonary embolus 0 1 1
Digestive Diarrhea 1 1 0
Hemic and lymphatic Neutropenia* 1/3 1/3 2/4
Febrile neutropenia* 3/1 2/0 4/2
Anaemia 2 2 3
Metabolic and nutritional Hypokalemia* 0/1 0/0 2/0
*Grade 3/4.
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ratios suggested that there was no evidence of a shift to a
higher or lower steady-state exposure to gefitinib when in
combination with vinorelbine or vinorelbine/cisplatin (Table
5). Hence, there would appear to be no effect on steady-state
exposure to gefitinib when it is given with either vinorelbine
alone or with the vinorelbine/cisplatin combination.
Effect of gefitinib on exposure to cisplatin.
Because of stability problems relating to the prepara-
tion of plasma ultrafiltrate, data from only six patients were
available. Although the intrapatient variability for cisplatin is
not known, comparison of individual AUC(0-t) ratios sug-
gested that there was no shift to a higher or lower exposure to
cisplatin when it was given in combination (Table 6). Thus,
from this limited data set, there would appear to be no effect
on exposure to cisplatin when given with vinorelbine in the
presence of steady-state levels of gefitinib.
Efficacy
Five patients (21.7%) had a confirmed partial response
for 3 months, including two who had responses that were
maintained for 6 months. An additional six patients had
stable disease, giving 11 patients with disease control (partial
response plus stable disease), nine of whom had disease
control for 3 months (Table 7). Five patients (21.7%)
progressed, and seven were not assessable for tumor response
(Table 7). Median survival for patients receiving gefitinib 250
mg/vinorelbine in group A was 2.8 months (95% confidence
interval [CI], 1.3–3.0); for patients receiving gefitinib 250
mg/vinorelbine plus cisplatin in group B, median survival
was 9.9 months (95% CI, 4.7, upper limit not calculable due
to insufficient events). Median progression-free survival for
patients receiving gefitinib 250 mg/vinorelbine (group A) was
1.5 months (95% CI, 1.3–1.8), and for patients receiving
gefitinib 250 mg/vinorelbine plus cisplatin (group B), it was
6.1 months (95% CI, 1.4, upper limit not calculable due to
insufficient events). Median survival and progression-free
survival for patients receiving gefitinib 500 mg in group B
were not calculable due to insufficient events.
DISCUSSION
Overall, the safety data from this trial are consistent
with previously conducted trials with gefitinib that showed a
higher incidence of AEs with 500 mg/day compared with 250
mg/day. The majority of the commonly reported gefitinib-
related AEs in this study, e.g., rash and diarrhea, were
consistent with those reported in other trials and with the AE
profile seen in trials of gefitinib monotherapy.6,7 Indeed,
during the gefitinib monotherapy period, grade 1 or 2 diarrhea
TABLE 4. Plasma Pharmacokinetic Parameters of Vinorelbine Alone and in Combination with Gefitinib: All Assessable
Patients Entered into the Trial
Group A Group B
Parameter (Units)
Summary
Statistics
Gefitinib
250 mg  Vinorelbine Gefitinib 250 mg
 Vinorelbine
and Cisplatin
Gefitinib
500 mg
 Vinorelbine
and Cisplatin
Patients, no. 5 5 6 6 6 6
Cmax, ng/mL gmean (CV%) 13.1 (81.0) 6.9 (45.7)) 11.0 (108) 13.0 (64.4) 15.4 (43.3) 16.4 62.4)
AUC(0-t), ng/hr/mL gmean CV%) 9.0 24.4) 7.5 57.0) 7.9 34.7) 8.7 35.1) 10.8 33.2) 12.3 42.6)
Individual ratios of
AUC(0-t) with and
without gefitinib,
range
0.40–1.60 0.67–1.78 0.52–1.27
Cmax, maximum plasma concentration; gmean, geometric mean; CV, coefficient of variation; AUC(0-t), area under the plasma concentration-time curve from time 0 to time of
the last quantifiable concentration.
TABLE 5. Pharmacokinetic Parameters for Gefitinib Given Alone and in Combination with Vinorelbine or Vinorelbine plus
Cisplatin: All Assessable Patients Entered into the Trial
Group A Group B
Parameter (Units)
Summary
Statistics
Gefitinib
250 mg  Vinorelbine
Gefitinib
250 mg
 Vinorelbine
and Cisplatin
Gefitinib
500 mg
 Vinorelbine
and Cisplatin
Patients, no. 5 5 7 7 6 6
Cmin
ss, ng/mL gmean (CV%) 418 33.7) 478 35.1) 231 42.1) 205 39.6) 283 78.6) 269 79.7)
AUC24
ss, ng/hr/mL gmean CV%) 11900 48.4) 13400 32.3) 7240 29.0) 7330 25.9) 8610 70.8) 9180 61.1)
Individual ratios of
AUC24
ss with and
without vinorelbine
(range)
0.83–1.94 0.76–1.32 0.93–1.40
Cmin
ss, minimum (trough) steady-state plasma concentration during the 24-hour dosing interval; gmean, geometric mean; CV, coefficient of variation; AUC24
ss, area under the
plasma concentration-time curve at steady state.
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was the most frequently occurring AE (one and two patients
in the 250- and 500-mg dose groups in group B, respectively).
However, with the combinations studied here, there was a
higher than expected incidence of hematologic AEs, specif-
ically febrile neutropenia and grade 3/4 neutropenia. This
unexpected and unacceptably high toxicity did not seem to be
related to a gefitinib-mediated drug interaction because phar-
macokinetic data demonstrated no effect on steady-state ex-
posure to gefitinib when given with chemotherapy or on
exposure to vinorelbine, given with or without cisplatin, in
the presence of steady-state levels of gefitinib. In INTACT
(IRESSA NSCLC Trial Assessing Combination Treatment)
1, the combination of gefitinib, cisplatin, and gemcitabine
showed no unexpected AEs.11 Recurrent febrile neutropenia
and neutropenia in the present study may have been exacer-
bated by chemotherapy dose reductions that were not always
followed as outlined in the protocol. In addition, some pa-
tients had their dose reduced and then subsequently reesca-
lated.
A planned phase II part of this trial did not proceed for
two main reasons. First, the combination of gefitinib and
vinorelbine was associated with unacceptable hematologic
toxicity in this trial and in a second trial involving gefitinib/
vinorelbine combination therapy, in which 72% of patients
experienced grade 3/4 neutropenia and three treatment-re-
lated deaths were recorded.17 Second, data from the INTACT
1 and 2 phase III trials showed that the addition of gefitinib
250 or 500 mg to the standard doublet chemotherapies gem-
citabine/cisplatin or carboplatin/paclitaxel did not confer a
statistically or clinically significant survival advantage com-
pared with a placebo/chemotherapy regimen in patients with
advanced NSCLC.
Based on these small numbers of patients, within-
patient data comparisons suggest that there was no pharma-
cokinetic interaction between cisplatin and gefitinib at either
gefitinib dose level. This result is consistent with an earlier
gefitinib combination study that investigated the potential for
a pharmacokinetic interaction with cisplatin when given as
the gemcitabine/cisplatin combination.10 Similarly, there was
no apparent pharmacokinetic interaction between gefitinib
and vinorelbine. This combination was the most likely source
of any interaction based on the possibility of CYP3A4 sub-
strate competition. The lack of interaction confirms the re-
sults of an in vitro study of the potential for a competitive
inhibition effect on CYP3A4 between gefitinib and vinorel-
bine that concluded that no drug-drug interaction would occur
in vivo when these two agents were combined.18
Antitumor activity was observed in both groups. A
greater number of patients receiving gefitinib 250 mg plus
vinorelbine/cisplatin (group B) had stable disease than those
patients receiving gefitinib 250 mg plus vinorelbine alone
(group A), although it is difficult to draw firm efficacy
conclusions for the different regimens due to the small patient
numbers in the treatment groups.
Research is warranted to identify the exact reason for
potentiation of vinorelbine myelosuppression when delivered
in patient receiving gefitinib. A possible explanation would
be gefitinib-induced cytochrome P-450 (CYP3A4) activity,
an enzyme responsible for the metabolism of a wide variety
of chemicals, including anticancer agents. Induction of
TABLE 6. Pharmacokinetic Parameters of Free Platinum (ng/mL)
Gefitinib 250 mg Gefitinib 500 mg
Parameter (Units)
Summary
Statistics Cisplatin
Cisplatin 
Gefitinib 250 mg Cisplatin
Cisplatin  Gefitinib
500 mg
Patients, no. 3 3 3 3
Cmax, ng/mL gmean (CV%) 1900 39.0) 1410 16.8) 1360 14.4) 1330 50.8)
AUC(0-t), ng/hr/mL gmean CV%) 3120 39.2) 2510 15.1) 2300 7.44) 2260 48.0)
Individual ratios of
free platinum
AUC(0-t) with and
without gefitinib
0.47
0.82
1.35
0.58
1.25
1.31
Cmax, maximum plasma concentration; gmean, geometric mean; CV, coefficient of variation; AUC(0-t), area under the plasma concentration-time curve from time 0 to time of
the last quantifiable concentration.
TABLE 7. Patients Experiencing Tumor Response, Stable Disease, or Disease Progression
Group A Group B
Best Overall Response
Gefitinib 250 mg/day
(n  6)
Gefitinib 250 mg/day
(n  8)
Gefitinib 500 mg/day
(n  9)
All Patients
(n  23)
Partial response, no. (%) 1 (16.7) 3 (37.5) 1 (11.1) 5 (21.7)
Stable disease, no. %) 0 2 (25.0) 4 (44.4) 6 (26.1)
Disease progression, no. %) 2 (33.3) 2 (25.0) 1 (11.1) 5 (21.7)
Not assessable, no. %) 3 (50.0) 1 (12.5) 3 (33.3) 7 (30.4)
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CYP3A4 by gefitinib has been suggested by a study demon-
strating that urinary 6-hydroxycortisol level, a cortisol me-
tabolite correlated with CYP3A4 activity, increased in pa-
tients receiving gefitinib.19 The cytochrome P-450 system
catalyzes the rate-limiting step in the overall metabolism and
subsequent elimination of many drugs and is known to be
involved in the metabolism of many anticancer drugs such as
vinca-alkaloid including vinblastine, vincristine, and vinorel-
bine.20
In conclusion, despite positive efficacy and pharmaco-
kinetic data, the combination of gefitinib with vinorelbine
alone or with vinorelbine plus cisplatin cannot be considered
acceptable due to a high incidence of hematologic toxicity,
specifically CTC grade 3/4 neutropenia and febrile neutrope-
nia. Unexpected myelotoxicity with the combination of ge-
fitinib and vinorelbine has also been reported in a small study
in Japanese patients.21 These data illustrate that it is not
possible to assume that because a new drug may be safely
combined with certain standard chemotherapy regimens (e.g.,
carboplatin/paclitaxel or cisplatin/gemcitabine in the case of
gefitinib) that it is safe to extrapolate results and combine the
agent with other regimens outside a clinical trial.
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